RaQualia Pharma Inc. (JP:4579) has released an update.
RaQualia Pharma Inc. reported a 39.1% increase in net sales for the first half of the fiscal year ending December 31, 2024, compared to the previous year, although the company faced operating and ordinary losses in the same period. The pharmaceutical company’s equity ratio declined from 88.7% to 55.6%, indicating a change in the company’s financial position. Despite the current losses, RaQualia forecasts a significant improvement by the end of the fiscal year, with an expected 138.5% increase in net sales and earnings per share of 10.91 yen.
For further insights into JP:4579 stock, check out TipRanks’ Stock Analysis page.
